Abstract
The intermediate-conductance Ca 2+ -activated K + channel K Ca 3.1 is involved in the promotion of tumor growth and metastasis, and is a potential therapeutic target and biomarker for cancer. Histone deacetylase inhibitors (HDACis) have considerable potential for cancer therapy, however, the effects of HDACis on ion channel expression have not yet been investigated in detail. The results of this study showed a significant decrease in K Ca 3.1 transcription by HDAC inhibition in the human breast cancer cell line YMB-1, which functionally expresses K Ca 3.1. A treatment with the clinically available, class I, II, and IV HDAC inhibitor, vorinostat significantly downregulated K Ca 3.1 transcription in a concentration-dependent manner, and the plasmalemmal expression of the K Ca 3.1 protein and its functional activity were correspondingly decreased. Pharmacological and siRNA-based HDAC inhibition both revealed the involvement of HDAC2 and HDAC3 in K Ca 3.1 transcription through the same mechanism. The downregulation of K Ca 3.1 in YMB-1 was not due to the upregulation of the repressor element-1 silencing transcription factor, REST and the insulin-like growth factor-binding protein 5, IGFBP5. The significant decrease in K Ca 3.1 transcription by HDAC inhibition was also observed in the K Ca 3.1-expressing human prostate cancer cell line, PC-3. These results suggest that vorinostat and the selective HDACis for HDAC2 and/or HDAC3 are effective drug candidates for K Ca 3.1-overexpressing cancers.
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Introduction
The Ca 2+ -activated K + (K Ca ) channel contributes to the feedback mechanism required to enhance Ca 2+ signaling by controlling Ca 2+ entry through Ca 2+ release-activated Ca 2+ channels in nonexcitable cells such as cancer and immune cells (Cahalan and Chandy 2009; Bergmeier et al. 2013; Huang and Jan 2014; Pardo and St€ uhmer 2014; Comes et al. 2015; Feske et al. 2015) . Based on the single-channel conductance, K Ca channels have been classified into large conductance (K Ca 1.1), intermediate conductance (K Ca 3.1, also known as IK Ca , SK4, and KCNN4) , and small conductance (K Ca 2.x) channels. The blockade of K Ca 3.1 inhibits proliferation and invasion during metastasis and/or promotes apoptosis in several cancer types including breast cancer (Wulff and Castle 2010; Ouadid-Ahidouch and Ahidouch 2013) . Breast cancer is the most commonly occurring malignancy among women, and K Ca 3.1 has been identified as one of the new loci associated with susceptibility to breast cancer by large-scale genotyping analyses (Michailidou et al. 2013) . Since K Ca 3.1 increased with the progression of breast cancer, it may be useful as a tumor marker to detect the malignancy grade during breast cancer progression (Haren et al. 2010) . The luteotropic hormone, prolactin (PRL) has been associated with an increased risk of breast cancer, and PRL-induced K Ca 3.1 activation promotes the proliferation of breast cancer cells (Faouzi et al. 2010) . Of the four K Ca 3.1 regulators identified to date (class II phosphatidylinositol 3 kinase C2b (PI3K-C2B), nucleoside diphosphate kinase-B (NDPK-B), protein histidine phosphatase 1 (PHPT1), and phosphatidylinositol 3-phosphate phosphatase myotubularin-related protein 6 (MTMR6), NDPK-B is involved in various cellular functions in cancer cells and is a potential therapeutic target for breast cancer (Attwood and Wieland 2015) . Histone deacetylase inhibitors (HDACis), which exhibit a broad spectrum of epigenetic activities, are emerging as anticancer drugs (Bose et al. 2014 ). The suberoylanilide hydroxamic acid vorinostat received FDA approval for the treatment of cutaneous T-cell lymphoma and is a panHDACi that inhibits class I, II, and IV HDAC subtypes. HDACis are a novel class of agents in the treatment of solid cancers (Slingerland et al. 2014) , and several clinical studies have been conducted on vorinostat as a combination therapy (Munster et al. 2011; Ramaswamy et al. 2012) . HDACis reverse DNA methylation in cancer cells, and have clinical activity in the treatment of cancers (West and Johnstone 2014) . We previously reported that the transcription of the Ca 2+ -activated Cl À channel TMEM16A is downregulated by vorinostat and the pharmacological and small interfering RNA (siRNA)-based blockade of HDAC3 (Matsuba et al. 2014) ; however, the regulation of other ion channels by HDAC inhibition remains to be elucidated. The destabilization of DNA methylation (hypermethylation or hypomethylation) in ion channels has been correlated with tumorigenesis and a poor prognosis . Hypomethylation of the K Ca 3.1 promoter has recently been associated with the upregulation of K Ca 3.1 in lung cancer cells (Bulk et al. 2015) . We herein demonstrated that the expression of K Ca 3.1 was downregulated in the human breast cancer cell line YMB-1 by treatment with the pan-HDAC inhibitor vorinostat. Pharmacological and siRNA-based HDAC inhibition experiments indicated that K Ca 3.1 transcription is regulated by HDAC2 and HDAC3 through the same mechanism. Taken together, these results suggest that vorinostat and HDAC2/3-selective inhibitors are effective against K Ca 3.1-overexpressing cancers and other K Ca 3.1-overexpressing disorders such as autoimmune and inflammatory diseases.
Materials and Methods

Cell culture and cell viability assay
The breast cancer cell lines MDA-MB-453, YMB-1, MCF-7, Hs578T-Luc, and BT-549 and the prostate cancer cell lines PC-3 and LNCaP (clone FGC) were supplied by the RIKEN BioResource Center (RIKEN BRC) (Tsukuba, Japan) and Health Science Research Resources Bank (HSRRB) (Osaka, Japan). They were maintained at 37°C, in 5% CO 2 with RPMI 1640, Dulbecco's modified Eagle's (DMEM), or Leibovitz's L-15 medium (Wako, Osaka, Japan) containing 10% fetal bovine serum (Sigma, St. Louis, MO) and a penicillin (100 units/mL)-streptomycin (0.1 mg/mL) mixture (Wako) (Matsuba et al. 2014) . A cell viability assay using WST-1 was performed as described in our previous study (Matsuba et al. 2014) . Briefly, using a density of 4 9 10 5 cells/mL, cells were cultured in duplicate on 96-well plates for 48 h (Fig. 1D ) or 72 h (Fig. 1C, E) . Absorbance was measured 2 h after the addition of WST-1 reagent into each well using the microplate reader MULTSCAN FC (Thermo Fisher Scientific, Yokohama, Japan) at a test wavelength of 450 nm and reference wavelength of 620 nm. A pair of control and treated samples was prepared from different passage cells, and then the same protocol was repeated on another day. Cell viability of the vehicle (0.1% dimethyl sulfoxide)-treated cells was arbitrarily expressed as 1.0.
Transfecting cells with siRNA
Lipofectamine RNAiMAX reagent was used for all siRNA transfection procedures (Matsuba et al. 2014) . Commer-cially available siRNA oligonucleotides against K Ca 3.1 (sc-91691), HDAC2 (sc-29345), HDAC3 (sc-35538), and control siRNA (type A) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The expression levels of the target transcripts were assessed 48 h after transfection of siRNAs using a real-time PCR assay, and cell viability was measured by the WST-1 assay.
RNA extraction, reverse transcription, and real-time PCR Total RNAs from normal human and tumor tissues were purchased from TaKaRa BIO (Osaka, Japan), BD Biosciences (San Jose, CA), and BioChain (Hayward, CA). Total RNAs from the primary tumor and corresponding metastatic tumor of the same donor (a 65-year-old female) were purchased from BioChain, who confirmed the expression of tumor-specific genes and tumor metastatic genes, respectively, in these tumors. Total RNA extraction from cell lines and reverse transcription were performed as previously reported (Matsuba et al. 2014) . cDNA products were amplified with gene-specific PCR primers, designated using Primer Express TM software (Ver 3.0.1; Life Technologies, Carlsbad, CA). Quantitative, real-time PCR was performed using SYBR Green chemistry on an ABI 7500 sequence detector system (Thermo- (Matsuba et al. 2014) , yielding the transcriptional quantitation of gene products relative to the endogenous standard, ACTB.
Overexpression of IGFBP5 in YMB-1 cells
The cDNA products from YMB-1 cells were amplified with KOD FX DNA polymerase (TOYOBO, Osaka, Japan) and PCR primers specific for human IGFBP5: IGFBP5 (NM_000599, 717-1629), 913 bp. The amplification profile was follows: a 2 min predenaturation step at 94°C, followed by 40 cycles of a 10 sec denaturation step at 98°C and a 1 min primer extension step at 68°C for 40 cycles. Obtained amplified products of full-length IGFBP5 were ligated into pcDNA3.1(+)/Neo r (Invitrogen) (pcDNA-IGFBP5). The nucleotide sequences of plasmid constructs were determined by Eurofins Genomics (Tokyo, Japan). YMB-1 cells were transiently transfected with pcDNA-IGFBP5 using Lipofectamine 2000 (Invitrogen). Forty-eight hours after transfection, the expression levels of IGFBP5 and K Ca 3.1 transcripts were determined by real-time PCR assay.
Protein expression analyses by Western blotting and immunocytochemistry
Proteins lysates were prepared from YMB-1 cells for Western blot analysis, as previously reported (Matsuba et al. 2014) . Protein expression levels were determined 48 h after the compound treatment. Equal amounts of protein (20 lg/lane) were subjected to SDS-PAGE (10%). Blots were incubated with anti-K Ca 3.1 (Alomone Labs, Jerusalem, Israel) and anti-ACTB (Medical & Biological Laboratories (MBL), Nagoya, Japan) antibodies, then incubated with anti-rabbit and anti-mouse horseradish peroxidase-conjugated IgG (Merck Millipore, Darmstadt, Germany), respectively. An enhanced chemiluminescence detection system (GE Healthcare Japan, Tokyo, Japan) was used to detect the bound antibody. The resulting images were analyzed by a VersaDoc5000MP device (BioRad Laboratories, Hercules, CA). In the immunocytochemical examination, living YMB-1 cells were harvested using a sterile cell scraper, and stained by an ATTO 488-conjugated anti-K Ca 3.1 (extracellular) antibody for live cell imaging (Alomone Labs). Stained cells were subjected to an analysis on a FACSCalibur flow cytometer using CellQuest software (BD Biosciences).
Measurements of K Ca 3.1 K + currents by whole-cell patch-clamp recordings Whole-cell patch-clamp experiments were performed as reported previously (Matsuba et al. 2014) . A pipette solution was used, with the following composition (in mmol/ L): 110 K-aspartate, 30 KCl, 1 MgCl 2 , 10 HEPES, 10 EGTA, and 2 Na 2 ATP (pH 7.2 by KOH). Ca 2+ concentrations (pCa 6.5) were determined using the WINMAXC program (Stanford University, Stanford, CA). Membrane currents were digitized using an analog-digital converter (PCI6229, National Instruments, Tokyo, Japan), and data acquisition and analysis were performed using WinWCP4.65, developed by Dr. John Dempster (University of Strathclyde, UK). The liquid junction potential between the pipette and bath solutions (À10 mV) was corrected. Cells were held at À80 mV and currents were evoked by pipette solutions containing Ca 2+ buffered at 300 nmol/L. Outward K + currents were determined by stepping the cell from À80 to +40 mV for 100 msec, and then to À40 mV to measure the tail current (see Fig. S3A ). A standard HEPES-buffered bathing solution was used, with the following composition (in mmol/L): 137 NaCl, 5.9 KCl, 2.2 CaCl 2 , 1.2 MgCl 2 , 14 glucose, and 10 HEPES (pH 7.4 by NaOH). All experiments were performed at 25 AE 1°C.
Measurement of the intracellular Ca
2+
concentrations by the fluorescent Ca 2+ indicator dye Cells were seeded onto 35 mm glass bottom dishes and cultured at 37°C in 5% CO 2 humidified incubator. Intracellular Ca 2+ concentration was measured using the fluorescent Ca 2+ indicator dye, Fura 2-AM. Cells were incubated with 10 lmol/L Fura 2-AM in normal HEPES solution for 30 min at room temperature. Cells loaded with Fura 2-AM were alternatively illuminated at wavelengths of 340 and 380 nm, and fluorescence images were recorded on the ORCA-Flash2.8 digital camera (Hamamatsu Photonics, Hamamatsu, Japan). Data collection and analyses were performed using an HCImage system (Hamamatsu Photonics). Images were measured every 5 sec. The fluorescent intensity of Fura 2 was expressed as measured 340/380 nm fluorescence ratios [ratio (340/380) Fig. S3B ). Ten minutes after 1st application of 2.2 mmol/L Ca 2+ , second one was performed in the presence of 1 mmol/L TRAM-34. The value of area under the curve (AUC) of the ratio (340/380) was obtained by the integration on the computer. The AUC value in the second application was normalized by that of the first one (relative AUC of [Ca 2+ ] i ).
Chemicals
The sources of pharmacological agents were as follows: TRAM-34 (Santa Cruz Biotechnology), ICA-17043 (Cheminstock Ltd., Shanghai, China), DiBAC 4 (3) (Invitrogen), DCEBIO (TOCRIS Bioscience, Ellisville, MO), paclitaxel (Sigma-Aldrich, St. Louis, MO, USA), PRL (Wako), WST-1 (Dojindo, Kumamoto, Japan), and Fura2-AM (Dojindo). HDAC inhibitors (vorinostat, AATB, T247, NCT-14b and NCO-04) were supplied by Professor Suzuki (KPUM). Others were obtained from Sigma-Aldrich or Wako Pure Chemical Industries (Tokyo, Japan).
Statistical analysis
The significance of differences among two and multiple groups was evaluated using the Student's t-test and Tukey's test after the F-test or ANOVA, respectively. Significance at P < 0.05 and P < 0.01 is indicated in the figures. Data are presented as the means AE SEM.
Results
High level expression of the K Ca 3.1 K + channel in breast tumor tissues and the breast cancer cell line, YMB-1 Figure 1A shows that K Ca 3.1 transcripts were more strongly expressed in human breast tumor tissues than in normal breast tissues. Of the five human breast cancer cell lines examined, the high level expression of K Ca 3.1 transcripts was detected in YMB-1 cells (Fig. 1B) . YMB-1 and MDA-MB-453 cells were human epidermal growth factor receptor 2 (HER2)-positive; however, no correlation was found between K Ca 3.1 and HER2. We next examined the effects of the selective K Ca 3.1 blocker, TRAM-34 and K Ca 2.x and K Ca 3.1 activator, DCEBIO on the viability of YMB-1 cells. Cell viability significantly decreased in YMB-1 cells treated for 72 h with 10 lmol/L TRAM-34 (Fig. 1C) , and significantly increased in those treated with 1 lmol/L DCEBIO (Fig. 1D) . Faouzi et al. (2010) have shown that K Ca 3.1 activity is significantly enhanced by a treatment with PRL and PRL-induced proliferation is inhibited by the pharmacological blockade of K Ca 3.1. In this study, PRL receptor (PRLR) transcripts were strongly expressed in YMB-1 cells (Fig. S1A ). As shown in Figure 1E , the enhancement induced in cell viability by the treatment with 200 nmol/L PRL for 72 h was significantly decreased by that with TRAM-34 (10 lmol/L). Of 51 K + channel subtypes (28 voltage-gated Kv subtypes, 15 two-pore domain K 2P subtypes, 7 Ca 2+ -activated K Ca subtypes, and inward-rectifier K ir 2.1), YMB-1 cells predominantly expressed K Ca 3.1 transcripts (Fig. S2A-F) , and no significant decrease in cell viability were detected in YMB-1 cells treated for 48 h with 10 mmol/L tetraethylammonium (TEA) (a Kv inhibitor) and 1 mmol/L Ba 2+ (a K 2P inhibitor) (Fig. S2G) .
Downregulation of K Ca 3.1 gene and protein expression in YMB-1 cells by the treatment with vorinostat
As shown in our previous study (Matsuba et al. 2014) , vorinostat (1 and 10 lmol/L) significantly inhibits the viability of YMB-1 cells in a concentration-dependent manner. Real-time PCR examinations revealed that the treatment of YMB-1 cells with vorinostat for 24 h significantly downregulated the expression levels of the K Ca 3.1 transcripts in a concentration-dependent manner (n = 4, P < 0.05 and 0.01 vs. vehicle control) ( Fig. 2A) . Similarly, the expression levels of the K Ca 3.1 proteins in YMB-1 cells were suppressed by the treatment with vorinostat for 48 h in a concentration-dependent manner (Fig. 2B) . Similar results were obtained from three independent experiments. The optical density of the K Ca 3.1 protein band signal relative to that of the ACTB one was calculated by ImageJ software (Ver. 1.42, NIH, Bethesda, MD), and protein expression levels in the vehicle control were then expressed as 1.00. Relative optical densities in vorinostat-treated groups (1 and 10 lmol/L) were 0.80 AE 0.04 (n = 3, P < 0.05) and 0.59 AE 0.05 (n = 3, P < 0.01). We also measured the protein expression levels of K Ca 3.1 in the plasma membrane with an ATTO 488-conjugated anti-K Ca 3.1 (extracellular) antibody (Alomone Labs), which has the ability to distinguish the extracellular region of K Ca 3.1 by a FCM analysis. A decrease in the percentage of K Ca 3.1-positive cells was observed by the treatment with 1 lmol/L vorinostat for 48 h (Fig. 2C and D) . In MDA-MB-453 cells weakly expressing K Ca 3.1, the percentage of ATTO 488-positive cells was less than 3% (not shown). The chemotherapy drugs paclitaxel (100 nmol/L) and bafilomycin-A (10 nmol/L, a vacuolar-ATPase inhibitor) markedly suppressed cell proliferation in these cell lines, whereas no suppressive effects were observed on K Ca 3.1 transcription (Fig. S1B) . Additionally, the inhibition of SIRT1 and 2 (class III HDAC subtypes) by NCO-04 (50 lmol/L) (Suzuki et al., 2012) did not significantly downregulate the expression of K Ca 3.1 in YMB-1 cells (Fig. S1C and D) .
Decrease in K Ca 3.1 activities in YMB-1 cells by the treatment with vorinostat
Outward K + currents were recorded by the application of depolarizing steps (from À80 to +40 mV for 100 msec) using the whole-cell configuration. Tail currents were then measured at À40 mV after depolarization to +40 mV for 100 msec. K Ca 3.1 K + currents were estimated as 1 lmol/L TRAM-34-sentitive components. Both peak and tail K Ca 3.1 K + currents sensitive to TRAM-34 were significantly smaller in 10 lmol/L vorinostat-treated than in vehicle-treated YMB-1 cells (Fig. 3) . Both peak (Fig. 3A) and tail (Fig. 3B) 80% decreased in vorinostat-treated YMB-1 cells. Next, we examined the effects of TRAM-34 on the SOCE in vehicle-and 10 lmol/L vorinostat-treated YMB-1 cells. In vehicle-treated YMB-1 cells, significant decrease in relative AUC of [Ca 2+ ] i due to membrane depolarization elicited by K Ca 3.1 inhibition was observed (Fig. 3C) , whereas it was disappeared in vorinostat-treated YMB-1 cells (Fig. 3D) . TRAM-34-induced decrease in the relative peak amplitude of transient Ca 2+ rise (peak 2/peak 1, see Fig. S3A ) was also disappeared by the treatment with 10 lmol/L vorinostat (not shown).
Identification of HDAC subtypes involved in the downregulation of K Ca 3.1 in YMB-1 cells by pharmacological and siRNA-based blockade of HDACs
The HDAC1, HDAC2, HDAC3, and HDAC6 subtypes are predominantly expressed in YMB-1 cells and human tumor breast tissues (M€ uller et al. 2013; Matsuba et al. 2014; Seo et al. 2014) . In order to identify the HDAC subtypes involved in the downregulation of K Ca 3.1 in YMB-1 cells, the following selective HDAC inhibitors were used: 30 nmol/L AATB, 300 nmol/L AATB, 1 lmol/ L T247, and 1 lmol/L NCT-14b for the selective inhibition of HDAC1, HDAC1/2, HDAC3, and HDAC6, respectively (Itoh et al. 2007; Methot et al. 2008; Suzuki et al. 2013) . As shown in Figure 4A , the transcription of K Ca 3.1 was significantly decreased by the treatment with 300 nmol/L AATB or 1 lmol/L T247 (for 48 h). The treatment with 300 nmol/L AATB plus 1 lmol/L T247 did not exhibit additive or synergistic inhibitory effects on K Ca 3.1 transcription (Fig. 4A ). The treatments with 30 nmol/L AATB and 1 lmol/L NCT-14b did not elicit any significant changes in K Ca 3.1 transcription. Similarly, the cell surface protein expression of K Ca 3.1 was significantly suppressed by the treatment with 300 nmol/L AATB or 1 lmol/L T247 (Fig. 4B ). In consistent with these results, decrease in relative AUC of [Ca 2+ ] i elicited by K Ca 3.1 inhibition was prevented in AATB (300 nmol/ L)-and T247 (1 lmol/L)-treated YMB-1 cells (Fig. S3C  and D) . We further examined the siRNA-based inhibition of HDAC subtypes. We first determined transfection conditions with more than 90% cell viability efficacy using Lipofectamine RNAiMAX. In YMB-1 cells, transfection efficacy was 50-60% under this optimum condition. HDAC2 or HDAC3 were 50% inhibited by HDAC2 or HDAC3 siRNAs (Fig. 5A and B) . Similar to the results shown in Figure 4 , K Ca 3.1 transcripts were downregulated by HDAC2 or HDAC3 siRNA (Fig. 5C ). The transcription of K Ca 3.1 was suppressed to a similar level by the transfection of K Ca 3.1 siRNA (Fig. 5C ). These results suggest that the inhibition of HDAC2 or HDAC3 may cause the downregulation of K Ca 3.1 in YMB-1 cells through the same mechanism. The expression levels of K Ca 3.1 transcripts were higher in the androgen-independent prostate cancer cell line PC-3 than in the androgen-dependent prostate cancer cell line LNCaP: 0.047 AE 0.002 and less than 0.0002 in arbitrary units, respectively. The downregulation of K Ca 3.1 by the treatment with vorinostat ( Fig. 6A ) and HDAC2 or HDAC3 inhibition (Fig. 6B ) was also detected in PC-3 cells. ] i was calculated as described in "Materials and Methods." Results are expressed as means AE SEM. Numbers used for the experiments are shown in parentheses. The significance of differences was evaluated using the Student's t-test. *, **P < 0.05, 0.01 versus vehicle control.
Effects of HDACis on the expression of K Ca 3.1 regulators in YMB-1 cells
Nucleotide diphosphate kinase (NDPK)-B is strongly expressed in many cancer types and, thus, is a potent therapeutic target for anticancer drugs (Attwood and Wieland 2015) . In T cells, NDPK-B is a well-known positive regulator of K Ca 3.1 (Di et al. 2010b; Ohya et al. 2014) . As shown in Figure 7A , NDPK-B transcripts were strongly expressed in human breast tumor tissues and YMB-1 cells. The pharmacological and siRNA-based blockade of HDAC2 and HDAC3 did not significantly affect the expression levels of NDPK-B transcripts (Fig. 7B-D) . Furthermore, the other positive and negative regulators of K Ca 3.1, and the transcriptional expression levels of PI3K-C2B, PHPT1, and MTMR6 (Srivastava et al. 2006 (Srivastava et al. , 2008 (Srivastava et al. , 2009 were not affected by the treatment with 10 lmol/L vorinostat (Fig. S4) .
Effects of HDAC inhibition on the expression of REST and IGFBP5 in YMB-1 cells
Repressor element 1-silencing transcription factor, REST (also known as neuron-restrictive silencer factor, NRSF) is known as a transcriptional repressor of K Ca 3.1 (Cheong et al. 2005; Ohya et al. 2011a) , and the transcription or protein degradation of REST is regulated by the treatment with HDACis (Taylor et al. 2012) . Therefore, we determined whether the downregulation of K Ca 3.1 by HDAC inhibition is due to an increase in REST expression in YMB-1 cells. As shown in Figure 8A and B, no significant changes in the transcriptional and protein expression levels of REST were found in vorinostat (1 and 10 lmol/ (Fig. 8C) .
It has been reported that insulin-like growth factorbinding protein 5 (IGFBP5) plays an important role in breast cancer progression and metastasis (Wang et al. 2008; Ghoussaini et al. 2014) . Recently, Akkiprik et al. (2015) have shown K Ca 3.1 gene expression is negatively correlated with IGFBP5 one in breast cancer tissues. Using total RNAs from the primary breast tumor and corresponding metastatic breast tumor of the same donor, we found that the expression levels of IGFPB5 transcripts were significantly higher in metastatic tissue than in primary tumor one (Fig. 8D) . As shown in Figure 8E , the treatment with 1 and 10 lmol/L vorinostat for 24 h caused significant increase in IGFBP5 transcripts. Therefore, we determined whether the downregulation of K Ca 3.1 by HDAC inhibition is related to the expression levels of IGFBP5 in YMB-1 cells. As shown in Figure 8F , no significant changes in the expression levels of K Ca 3.1 transcripts were found in IGFBP5-overexpressing YMB-1 cells (Fig. 8C ) when IGFBP5 transcription was over 10-fold increased by the transfection of pcDNA-IGFBP5 (not shown). These results indicated that K Ca 3.1 transcription was not regulated by REST and IGFBP5 in YMB-1 cells.
Expression of HDAC2, HDAC3, and K Ca 3.1 in human primary and metastatic breast tumor tissues
In various cancer types including breast cancer, the high level expression of K Ca 3.1 is associated with a high metastatic risk (Rabjerg et al. 2015) . Since K Ca 3.1 levels increase with the progression of breast cancer, K Ca 3.1 may be useful for detecting malignancy grade during breast cancer progression (Haren et al. 2010) . Using total RNAs from the primary breast tumor and corresponding metastatic breast tumor of the same donor, we found that the expression levels of K Ca 3.1 transcripts were lower in metastatic tissues than in primary tumor tissues (Fig. 9A) . The expression levels of HDAC2 (Fig. 9B) and HDAC3 (Fig. 9C) transcripts were also significantly lower in metastatic tissues. These results suggest that the upregulation of K Ca 3.1 through HDAC2 and HDAC3 enhancements may be responsible for the pathogenesis of aggressive rather than metastatic breast cancer. Results are expressed as means AE SEM. The numbers used for the experiments are shown in parentheses. The significance of differences among two and multiple groups was evaluated using the Student's t-test and Tukey's test. **P < 0.01 versus normal tissues.
Discussion
The intermediate-conductance Ca 2+ -activated K + channel, K Ca 3.1 has oncogenic potential and is a therapeutic target for K Ca 3.1-positive cancers such as renal (Rabjerg et al. 2015) , lung (Bulk et al. 2015) , hepatic, prostate cancers (Ohya et al. 2009), and glioblastoma (D'Alessandro et al. 2013) . In breast cancer, K Ca 3.1 is associated with tumor progression and metastasis (Ouadid-Ahidouch et al. 2004; Faouzi et al. 2010; Haren et al. 2010) . HDACis have potential as agents for the treatment of solid tumors including breast cancer (Slingerland et al. 2014) , however, their effects on ion channel expression have not yet been elucidated in detailed. The main results of this study are as follows. (1) The clinically available pan-HDAC inhibitor, vorinostat significantly downregulated K Ca 3.1 transcription in the human breast cancer cell line YMB-1 (see HDAC2 and HDAC3 are strongly expressed in aggressive breast tumor subtypes (Müller et al. 2013) . Their expression levels are also higher in HER2-positive breast tumor subtypes: 44% and 52% for HDAC2 and HDAC3, respectively. Consistent with this finding, HER2-positive YMB-1 and MDA-MB-453 cells strongly expressed HDAC1, 2, and 3 ( Fig. S5A and B) (Matsuba et al. 2014) . However, the expression levels of K Ca 3.1 transcripts markedly differed between these cell types (Fig. 1B) . No correlation was detected between the expression levels of HER2 and K Ca 3.1 in human primary breast cancer tissues (Fig. S5C) . Furthermore, HDAC1, HDAC2, and HDAC3 are highly expressed in human prostate cancer (Weichert et al. 2008) . The expression levels of HDAC2 were previously reported to be high in patients with Gleason score 7 (Weichert et al. 2008) . HDAC3 is also expected to become a potent therapeutic target for prostate cancer due to the consistently high rate of HDAC3 positivity (Weichert et al. 2008) . We previously demonstrated that HDAC2 and HDAC3 were both predominatly expressed in K Ca 3.1-expressing PC-3 cells (Matsuba et al. 2014) , while the expression level of K Ca 3.1 was found to be prominent in biopsy samples from patients with midgrade malignancy (Gleason score 5-6) (Ohya et al. 2009 ). These findings suggest that selective HDAC2 and 3 inhibitors have potential as therapeutic agents for K Ca 3.1-positive cancer.
HDACis upregulate tumor suppressor genes via histone hyperacetylation. It has been reported that the expression levels of REST and IGFBP5 is negatively correlated with that of K Ca 3.1 in proliferative cells including breast cancer calls (Cheong et al. 2005; Ohya et al. 2011a; Akkiprik et al. 2015) . The transcription or protein degradation of REST is regulated by the treatment with HDACis in medulloblastoma (Taylor et al. 2012) , however, this study showed no significant changes in the expression level of REST by the treatment with HDACis in YMB-1 cells (Fig. 8A and B) . In addition, no significant changes in the expression level of K Ca 3.1 transcripts were detected by the siRNA-based blockade of REST expression in YMB-1 cells (Fig. 8C) . These suggest that the downregulation of K Ca 3.1 by HDAC inhibition is not due to the upregulation of REST in YMB-1 cells. On the other hand, the expression level of IGFBP5 transcripts was significantly increased by vorinostat (Fig. 8D) . In gastrointestinal stromal tumors, the expression level of the Ca 2+ -activated Cl À channel ANO1/ TMEM16A was negatively correlated with that of IGFBP5 (Simon et al. 2013) . This study showed no significant downregulation of K Ca 3.1 by the overexpression of IGFBP5 in YMB-1 cells (Fig. 8F) . Of seven IGFBP subtypes (IGFBP1-7), IGFBP2 is predominatly expressed in YMB-1 cells, and no significant changes in K Ca 3.1 expression was caused by the overexpression of IGFBP2 (not shown). The destabilization of DNA methylation (hypermethylation or hypomethylation) in ion channels has been correlated with tumorigenesis and a poor prognosis . Hypomethylation of the K Ca 3.1 promoter has recently been associated with the upregulation of K Ca 3.1 in aggressive nonsmall-cell lung cancer (Bulk et al. 2015) , suggesting that the upregulation of , and HDAC3 (C) in human primary and metastatic breast tumors. Expression levels were expressed as the ratio to ACTB. Results are expressed as means AE SEM. The numbers used for the experiments are shown in parentheses. The significance of differences was evaluated using the Student's t-test. **P < 0.01 versus primary breast tumors. Haren et al. (2010) , this study showed that K Ca 3.1 was associated with the enhancement of breast cancer cell proliferation (Fig. 1) . Large-conductance K Ca 1.1 and small-conductance K Ca 2.3 have been implicated in metastasis by facilitating breast cancer cell migration (Khaitan et al. 2009; Chantô me et al. 2013) . Metalloproteinases 2 and 9 (MMP-2 and MMP-9) have been associated with breast cancer invasion (Jaafar et al. 2014; Vucemilo et al. 2014) , and the reduction in MMP-2 may play a role in the suppressive effects of the K Ca 3.1 blocker on breast cancer migration and invasion (Zhang et al. 2015) . Similar findings have been reported in glioma cells (D'Alessandro et al. 2013; Aroui et al. 2015) . However, the expression levels of MMP-2 and MMP-9 were very low in YMB-1, and no significant changes were found in their expression by HDAC inhibition or pharmacological K Ca 3.1 blockade (not shown).
HDACis were primarily developed as antitumor agents, but are currently being explored for the treatment of neurodegenerative, immunological, metabolic, inflammatory, atopic, and cardiovascular disorders. Felice et al. (2015) recently showed that HDAC2 and HDAC3 isoforms were involved in chronic intestinal inflammation, and HDAC inhibition decreased disease responses in inflammatory bowel disease (IBD). HDACis including vorinostat ameliorate intestinal inflammation by inhibiting inflammatory cytokine production in the CD4 + T cells of IBD model mice (Glauben et al. 2006) . Recent studies including our previous study demonstrated that the upregulation of K Ca 3.1 in CD4 + T cells was involved in the pathogenesis of IBD, and the pharmacological blockade of K Ca 3.1 elicited a significant decrease in IBD disease severity including intestinal inflammation (Di et al. 2010a; Ohya et al. 2014) . Gillespie et al. (2012) also found that a selective HDAC3 inhibitor reduced the production of the proinflammatory cytokine, IL-6 in mononuclear cells from rheumatoid arthritis patients. The pharmacological and genetic inhibition of K Ca 3.1 was previously shown to suppress IL-6 levels in rheumatoid arthritis patients and allergic rhinitis model mice (Friebel et al. 2015; Lin et al. 2015) . Furthermore, we reported the inhibition of IL-6 transcription by the pharmacological blockade of K Ca 3.1 in colonic inflammation in IBD model mice (Ohya et al. 2014) . These suggest selective HDAC inhibition of HDAC2 and/or HDAC3 as a new therapeutic strategy to improve chronic inflammatory diseases.
In conclusion, this study demonstrated that the selective inhibition of HDAC2 and/or HDAC3 is a novel therapeutic strategy for drug development focused on K Ca 3.1-expressing cancer cells such as aggressive breast and prostate cancers. Moreover, HDAC2 and/or HDAC3 may become therapeutic targets for the treatment of chronic inflammatory and atopic disorders.
